

Please Direct All Correspondence to Customer Number **30,313**

TRANSMITTAL LETTER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Applicant : Goddard, et al. (as amended)
App. No : 10/063,554
Filed : May 2, 2002
For : AN ANTIBODY TO A POLYPEPTIDE
ENCODED BY A NUCLEIC ACID OVER-
EXPRESSED IN NORMAL STOMACH
TISSUE AND RECTUM TUMOR (as
amended)
Examiner : Daniel E. Kolker
Art Unit : 1646

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all
marked attachments are being deposited with
the United States Postal Service as first-class
mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on

July 11, 2005

(Date)


AnneMarie Kaiser, Reg. No. 37,649

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:


Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing 11 references and enclosing 11 non-patent references.
- (X) Check in the amount of \$180.00.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

07/14/2005 HGUTEMAI 00000018 10063554

01 EC:1806 180.00 OP


AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Applicant : Goddard, et al. (as amended)
App. No : 10/063,554
Filed : May 2, 2002
For : AN ANTIBODY TO A POLYPEPTIDE
ENCODED BY A NUCLEIC ACID OVER-
EXPRESSED IN NORMAL STOMACH
TISSUE AND RECTUM TUMOR (as
amended)
Examiner : Daniel E. Kolker
Art Unit : 1646

CERTIFICATE OF MAILING

I hereby certify that this correspondence
and all marked attachments are being
deposited with the United States Postal
Service as first-class mail in an envelope
addressed to: Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-
1450, on

July 11, 2005

(Date)


AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 11 references to be considered by the Examiner. Also enclosed are 11 foreign patent references and/or non-patent literature as listed on the Supplemental Information Disclosure Statement.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 11, 2005By: 

AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30313
(619) 235-8550

07/14/2005 HGUTEM1 00000018 10063554

01 FC:1806

180.00 DP

1807554
071105

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/063,554
Filing Date	May 2, 2002
First Named Inventor	Goddard, et al. (as amended)
Art Unit	1646
Examiner	Daniel E. Kolker
Attorney Docket No.	GNE.3230R1C37

(Multiple sheets used when necessary)

SHEET 1 OF 1

JUL 13 2005

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , Vol. 15, No. 16, pp. 4392-4401.	
	2	GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C β II Is an Early Promotive Event in Colon Carcinogenesis, <i>Cancer Research</i> , Vol. 61, pp.1375-1381.	
	3	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
	4	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	5	HANCOCK, W. S. 2004. Do We Have Enough Biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.	
	6	HAYNES, et al., 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , Vol. 19, pp. 1862- 1871.	
	7	HU, et al. 2003. Analysis of Genomic and Proteomic Data Using Advanced Literature Mining. <i>Journal of Proteome Research</i> , Vol. 2, pp. 405-412.	
	8	JANG A. Hill RP, Sept. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> 15(5): pp. 469-483	
	9	KONOPKA, et al. June 1986. Variable Expression of the Translocated c-abl Oncogene in Philadelphia-Chromosome-Positive B-Lymphoid Cell Lines from Chronic Myelogenous Leukemia Patients, <i>National Academy of Sciences of the United States of America</i> , Vol. 83, No. 11, pp. 4049-4052	
	10	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.	
	11	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	

1807488
071105

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.